EMD Serono’s Tepmetko is one of a number of targeted cancer therapies that have passed FDA muster in the past year. The decision sets up the German company’s pill for head-to-head competition with a Novartis drug targeting the same genetic signature.
Another innovation hub, in the southern city of Guangzhou, is planned for November. To date, six startups in China and other Asian countries have taken part in the German drugmaker's accelerator program.
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
TocopheRx is developing an infertility drug that's meant to sidestep IVF injections - converting in vitro fertilization into a completely oral regimen for both men and women. It's raising a $22 million Series A.